mut. BRAF sel. heterobifunctional degrader

efficacy in xenograft at 50 mg/kg IP BID

VHL-based degrader from vemurafenib

Nat. Comm., Feb. 10, 2021

Yale University, New Haven, CT


13. The Yale BRAF-targeting PROTAC SJF-0628 is a VHL-based heterobifunctional degrader with in vivo activity in a xenograft model (50 mg/kg BID IP). Though mutant BRAF is a well-validated…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: